← Back to Search

GLP-1 Receptor Antagonist

Exendin-9,39 for Type 2 Diabetes

Phase 3
Waitlist Available
Research Sponsored by Adrian Vella
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Weight-stable, non-diabetic subjects
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up average concentration over the -30 to 0 minutes of study
Awards & highlights

Study Summary

This trial will test whether GLP-1, a hormone made by the body, can help people with type 2 diabetes produce insulin.

Eligible Conditions
  • Type 2 Diabetes
  • Healthy Subjects

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~average concentration over the -30 to 0 minutes of study
This trial's timeline: 3 weeks for screening, Varies for treatment, and average concentration over the -30 to 0 minutes of study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: Exendin-9,39Active Control1 Intervention
Exendin-9,39 infusion
Group II: Saline + Intralipid/HeparinActive Control1 Intervention
Induction of acute insulin resistance during Saline infusion
Group III: Exendin-9,39 + Intralipid/HeparinActive Control1 Intervention
Induction of acute insulin resistance during Exendin-9,39 infusion
Group IV: SalinePlacebo Group1 Intervention
Saline infusion

Find a Location

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,338 Previous Clinical Trials
4,314,176 Total Patients Enrolled
Adrian VellaLead Sponsor
8 Previous Clinical Trials
186 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research include elderly patients who are over the age of 75?

"The age limit for this clinical trial is 65 years old. Any patients that are over 25 and younger than the age limit are eligible to enroll."

Answered by AI

Exendin-9,39 is most commonly associated with which treatments?

"Exendin-9,39 is frequently given to patients suffering from ascorbic acid deficiency. However, this medication can also be taken to treat conditions related to medical devices, sprains, and unstable angina pectoris."

Answered by AI

Have similar medical trials been conducted before?

"Since its first study in 2006, Exendin-9,39 has undergone extensive clinical research with 60 active trials today. These trials are conducted in 220 cities across 23 countries and have involved415 people total."

Answered by AI

Is Exendin-9,39 dangerous for human beings?

"Exendin-9,39 is a medication that has undergone Phase 3 clinical trials. This signifies that, while there is data affirming its efficacy, multiple rounds of testing have also backed up its safety. Our team rates its safety as a 3."

Answered by AI

Are there any other peer-reviewed papers that mention Exendin-9,39?

"There are a total of 60 ongoing studies regarding Exendin-9,39. Of these, 18 are in Phase 3. Most trials for Exendin-9,39 are located in Nieuwegein and Utrecht, but there are a total of 420 medical centres running trials for this medication."

Answered by AI
~6 spots leftby Mar 2025